Multiple myeloma: Changes in serum C-terminal telopeptide of collagen type i and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis

European Journal of Haematology

Volumn 84, Issue 5, 2010, Pages 412-420

  Lund, Thomas ^a,b   Abildgaard, Niels ^c   Andersen, Thomas L ^b   Delaisse, Jean Marie ^b   Plesner, Torben ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bisphosphonates; Bone disease; Bone markers; Multiple myeloma; Osteolysis

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE DEFECT; BONE DISEASE; BONE REMODELING; BONE TURNOVER; DISEASE EXACERBATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE REMODELING; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOLYSIS; PEPTIDE FRAGMENTS; PROCOLLAGEN;

EID: 77951056556     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01417.x     Document Type: Article

References (46)

1. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003 78 : 21 33.
2. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007 357 : 2123 2132.
3. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007 370 : 1209 1218.
4. Sonneveld P, Hajek R, Nagler A, Spencer A, Blade J, Robak T, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008 112 : 1529 1537.
5. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001 98 : 11581 11586.
6. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001 98 : 3527 3533.
7. Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003 63 : 5438 5445.
8. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000 96 : 671 675.
9. Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000 96 : 1953 1960.
10. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003 349 : 2483 2494.
11. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005 106 : 3160 3165.
12. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005 106 : 2472 2483.
13. Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007 109 : 3024 3030.
14. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996 334 : 488 493.
15. Body JJ. The risk of cumulative renal effects of intravenous bisphosphonates. Support Cancer Ther 2006 3 : 77 83.
16. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003 61 : 1115 1117.
17. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006 81 : 1047 1053.
18. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007 25 : 2464 2472. (Pubitemid 46999218)
19. D'Sa S, Abildgaard N, Tighe J, Shaw P, Hall-Craggs M. Guidelines for the use of imaging in the management of myeloma. Br J Haematol 2007 137 : 49 63.
20. Abildgaard N, Glerup H, Rungby J, dix-Hansen K, Kassem M, Brixen K, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000 64 : 121 129.
21. Delmas PD, Schlemmer A, Gineyts E, Riis B, Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991 6 : 639 644.
22. Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003 120 : 235 242.
23. Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004 89 : 567 577.
24. Alexandrakis MG, Passam FH, Malliaraki N, Katachanakis C, Kyriakou DS, Margioris AN. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin Chim Acta 2002 325 : 51 7.
25. Bataille R, Delmas PD, Chappard D, Sany J. Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer 1990 66 : 167 172.
26. Corso A, Arcaini L, Mangiacavalli S, Astori C, Orlandi E, Lorenzi A, et al. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica 2001 86 : 394 398.
27. Jakob C, Sterz J, Liebisch P, Mieth M, Rademacher J, Goerke A, et al. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia 2008 22 : 1767 1772.
28. Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999 14 : 792 801.
29. Woitge HW, Horn E, Keck AV, Auler B, Seibel MJ, Pecherstorfer M. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem 2001 47 : 686 693.
30. Bacovsky J, Scudla V, Vytrasova M, Budikova M, Myslivecek M. Monitoring of bone resorption and bone formation in multiple myeloma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2002 146 : 59 61.
31. Terpos E, Palermos J, Tsionos K, Anargyrou K, Viniou N, Papassavas P, et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 2000 65 : 331 336.
32. Terpos E, Politou M, Szydlo R, Nadal E, Avery S, Olavarria E, et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 2004 18 : 1420 1426. Ref ID: 98.
33. Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005 19 : 1969 1976.
34. Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol 2006 76 : 399 404.
35. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006 20 : 1467 1473.
36. Qvist P, Munk M, Hoyle N, Christiansen C. Serum and plasma fragments of C-telopeptides of type I collagen (CTX) are stable during storage at low temperatures for 3 years. Clin Chim Acta 2004 350 : 167 173.
37. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008 111 : 2516 2520.
38. Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 2003 88 : 5059 5075.
39. Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E, et al. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma 2007 7 : 346 353.
40. Terpos E, de la FJ, Szydlo R, Hatjiharissi E, Viniou N, Meletis J, et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 2003 106 : 455 457.
41. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006 135 : 688 692.
42. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003 18 : 859 867.
43. Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992 66 : 337 341.
44. Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991 88 : 62 6.
45. Laroche M, Attal M, Dromer C. Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma. Clin Rheumatol 1996 15 : 347 352.
46. Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992 49 : 192 198.